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Fibrillin-1 (FBN1) mutations associated with Marfan
syndrome lead to an increase in transforming growth
factor b (TGF-b) activation in connective tissues re-
sulting in pathogenic changes including aortic dilata-
tion and dissection. Since FBN1 binds latent TGF-b
binding proteins (LTBPs), the major reservoir of
TGF-b in the extracellular matrix (ECM), we investi-
gated the structural basis for the FBN1/LTBP1
interaction. We present the structure of a four-
domain FBN1 fragment, EGF2-EGF3-Hyb1-cbEGF1
(FBN1E2cbEGF1),which reveals anear-lineardomainor-
ganization. Binding studies demonstrate a bipartite
interaction between a C-terminal LTBP1 fragment
and FBN1E2cbEGF1, which lies adjacent to the latency-
associated propeptide (LAP)/TGF-b binding site of
LTBP1. Modeling of the binding interface suggests
that, rather than interacting along the longitudinal
axis, LTBP1anchors itself to FBN1using two indepen-
dent epitopes. As part of this mechanism, a flexible
pivot adjacent to the FBN1/LTBP1 binding site allows
LTBP1 tomake contacts with different ECM networks
while presumably facilitating a force-induced/trac-
tion-based TGF-b activation mechanism.
INTRODUCTION
The fibrillin/latent transforming growth factor b (TGF-b) binding
protein (LTBP) family of extracellular matrix (ECM) proteins are
calcium-binding glycoproteins whose domain organization is
dominated by multiple tandem repeats of calcium-binding
epidermal growth factor-like (cbEGF) and TGF-b binding pro-
tein-like (TB) domains (Figure 1A) (Robertson et al., 2011). Fibril-
lin (FBN) is an evolutionarily ancient protein which plays an
important structural role in connective tissues through its
higher-order association into 10–12 nm microfibrils (Jensen
et al., 2012; Keene et al., 1991). The LTBPs are responsible for
sequestering the small latent complex, comprising latency-
associated propeptide (LAP) and TGF-b in the matrix (Saharinen
and Keski-Oja, 2000). Recent research suggests that FBN also
has an important regulatory role in development and homeosta-
sis by transmitting diverse information about the extracellular1208 Structure 25, 1208–1221, August 1, 2017 ª 2017 The Authors. P
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duction might occur through direct interactions between FBN
and cell-surface integrin receptors (Pfaff et al., 1996; Sakamoto
et al., 1996; Zeyer and Reinhardt, 2015) and/or through its direct
or indirect sequestration of growth factors including various
TGF-b superfamily members (Robertson and Rifkin, 2016).
Studies of genetic diseases and mouse models have demon-
strated important physiological connections between FBN1 and
TGF-bsignaling in vivo.Marfansyndrome,causedby loss-of-func-
tion FBN1mutations, can result in aortic dilatation and dissection,
aswell as pathological changes to the skeleton and the eye (Doyle
et al., 2012). Inhibition of TGF-b, either directly using neutralizing
antibodies or indirectly using drugs such as Losartan, has demon-
strated reversal of pathological changes in the aorta, lung, and
skeleton in FBN1 mouse models, suggesting that FBN1 levels in
the ECM influence TGF-b activity (Cohn et al., 2007; Habashi
et al., 2011; Lima et al., 2010; Neptune et al., 2003). Subsequent
studies have shown that both integrin levels and changes in me-
chano-sensation by the angiotensin receptor can furthermodulate
conditional FBN knockout mouse phenotypes indicating a com-
plex cell/matrix interplay (Cook et al., 2014, 2015).
Cell biology studies have shown co-localization of FBN micro-
fibrils with LTBPs in skin (Raghunath et al., 1998), bone (Dallas
et al., 1995), and tissue culture (Dallas et al., 2000; Taipale et al.,
1996). The LTBP isoforms LTBP1, 3, and 4 all covalently bind
the small latent complex (comprising LAP and TGF-b) (Robertson
et al., 2015; Saharinen and Keski-Oja, 2000). Subsequent
biochemical studies have shown that there are interactions be-
tween eukaryotically expressed recombinant fragments of the
N-terminal region of FBN1 and the C-terminal region of several
of the LTBPs (Isogai et al., 2003; Massam-Wu et al., 2010; Ono
et al., 2009). Thesestudies identified theEGF2/EGF3andHybrid1
(Hyb1) domains of FBN1 and the TB3-EGF3-cbEGF15 region of
LTBP1 as being important for binding. Collectively, mouse
models, cell biology, and biochemical data place FBN, LTBP,
and TGF-b at the center of a complex mechano-sensory network
within connective tissue, the structural basis ofwhich is unknown.
Here the structural basis for the interaction between FBN1 and
LTBP1 has been investigated utilizing biophysical and biochem-
ical techniques. The solution structure of a four-domain LTBP1-
binding FBN1 fragment, EGF2-EGF3-Hyb1-cbEGF1, based on
nuclear magnetic resonance (NMR) and small-angle X-ray scat-
tering (SAXS) data, reveals a near-linear arrangement of do-
mains, completing the structure of the N terminus of FBN1.
Detailed dissection of the binding interface and subsequent
modeling of the LTBP1/FBN1 complex indicates that LTBP1ublished by Elsevier Ltd.
commons.org/licenses/by/4.0/).
Figure 1. Overlapping Protein Constructs Used to Study the Interaction between FBN1 and LTBP1
(A) The FBN1 and LTBP1 constructs used in this study are shown in the context of the domain organization of the full-length proteins. ‘‘H6’’ in front of the
constructs denotes that the protein is expressed with a hexa-His tag and the brackets indicate that it can be cleaved by factor Xa without degradation of the
protein. Domain numbers for the TB and Hyb domains and for selected cbEGF domains are indicated and are color coded according to domain type.
(B) Multi-cycle SPR data showing the concentration-dependent interaction of the LTBP1TB3cbEGF15 construct with FBN1E2cbEGF1 amine-coupled to the surface of
the sensor chip.
(C) Plate-binding assay showing the interaction of the His-tagged three-domain LTBP1TB3cbEGF15 (B) or two-domain LTBP1TB3E3 (A) constructs with a four-
domain FBN1E2cbEGF1 construct immobilized on the plate surface. No binding was seen with a control three-domain His-tagged Notch EGF9-11 construct (6).
The data presented are from a single plate; three repeats of each protein concentration were carried out to determine experimental error (SD). See also Figure S1.binds FBN1 via its C-terminal TB3 and EGF3 domains in a bipar-
tite interaction involving two different faces of the FBN1 mole-
cule. This localized interaction ensures tight binding to FBN1
while allowing the N-terminal region of LTBP1 to engage with
other ECM networks. This may facilitate regulated TGF-b activa-
tion by traction-based mechanisms involving integrins, and sug-
gests that FBN1 deficiency precludes optimal localization of
LTBP in the ECM for regulated TGF-b activation.
RESULTS AND DISCUSSION
Binding Studies Identify a Specific Interaction between
LTBP1 and FBN1
Previous data utilizing eukaryotically expressed fragments iden-
tified a specific interaction between the C-terminal region ofLTBP1 and the N-terminal region of FBN1 (Isogai et al., 2003;
Ono et al., 2009). Here, overlapping protein fragments derived
from the N terminus of FBN1 and the C terminus of LTBP1
have been bacterially expressed and refolded in vitro (Figures
1A and S1), as described previously (Robertson et al., 2013a,
2013b; Yadin et al., 2012), to probe their interaction at themolec-
ular level and to determine a model of the interaction complex.
We observed a specific interaction between a three-domain
C-terminal LTBP1TB3cbEGF15 construct and a four-domain
FBN1E2cbEGF1 construct using both surface plasmon resonance
(SPR) and a plate-based binding assay (Figures 1B and 1C). This
confirms the interaction reported previously using eukaryotically
expressed material (Isogai et al., 2003; Ono et al., 2009), and
demonstrates that the core recognition elements are contained
in the amino acid sequence of the proteins.Structure 25, 1208–1221, August 1, 2017 1209
Figure 2. Interactions of FBN1 and LTBP1 Domain Constructs Measured by SPR
(A) Single-cycle SPR data showing the interaction of three overlapping two-domain LTBP1 constructs (analytes) with three SPR flow cells coated with different
FBN1 constructs. LTBP1 concentrations are shown in mM above the relevant part of the sensorgram for the highest concentration single-cycle experiment. The
FBN1 construct containing the cbEGF22-TB4-cbEGF23 domains was used as a control.
(B) Plot of SPR responses from three different LTBP1 constructs binding to FBN1E2cbEGF1; this demonstrates that for the interaction with FBN1E2cbEGF1
Kd(TB3E3) < Kd(E3cbEGF15) < Kd(cbEGF14TB3). Concentrations are shown on a logarithmic scale to accommodate the weak binding of LTBP1
cbEGF14TB3.
(C) Schematic representation of the interaction model suggested by the SPR data. See also Figures S1 and S2.We compared the binding of the three-domain
LTBP1TB3cbEGF15 and two-domain LTBP1TB3E3 constructs to the
four-domainFBN1E2cbEGF1 construct using theplate-basedassay
(Figure 1C). Thebinding responses of the twoLTBP1 fragments to
FBN1 are the same, suggesting that the cbEGF15 domain of
LTBP1 does not contribute to the interaction with FBN1.
To dissect the interaction further using SPR, analytes
LTBP1TB3E3, LTBP1E3cbEGF15, and LTBP1cbEGF14TB3, each con-
taining a pair of domains, were flowed over immobilized
FBN1E2cbEGF1 (Figure 2A). The largest response was observed
for LTBP1TB3E3 with moderate binding for LTBP1E3cbEGF15 and1210 Structure 25, 1208–1221, August 1, 2017even weaker binding for LTBP1cbEGF14TB3 (Figure 2B). The
high-affinity binding observed for LTBP1TB3E3 suggests that
the TB3 and EGF3 domains, rather than the flanking cbEGF14
and cbEGF15 domains, are important for maximal binding. The
observation of weak binding for both the LTBP1cbEGF14TB3 and
LTBP1E3cbEGF15 constructs, which do not have any domains in
common, suggests that more than one domain from LTBP1 in-
teracts with FBN1. The relative binding strengths of the LTBP1
fragments also suggest that the EGF3 domain of LTBP1 makes
a more significant contribution to the interaction with FBN1
than the TB3 domain of LTBP1.
Figure 3. HSQC Titration Data Highlights Multiple Binding Sites in Both FBN1 and LTBP1
Titrations were carried out by sequential addition of lyophilized unlabeled protein to 15N-labeled protein samples and monitored using 1H-15N HSQC spectra.
(A andB) Peakswere observed to shift in titrations of (A) 15N-LTBP1cbEGF14TB3with FBN1E2cbEGF1 added, or of (B) 15N-FBN1E2cbEGF1 with LTBP1cbEGF14TB3 added.
The combined 1HN and 15N chemical shift change is plotted as a function of protein sequence.
(C and D) Peak broadening was observed in titrations of (C) 15N-LTBP1E3cbEGF15 with FBN1E2cbEGF1 added or of (D) 15N-FBN1E2cbEGF1 with LTBP1E3cbEGF15
added. Peak intensity changes,measured as the ratio of peak intensity in the absence of ligand to that in the presence of ligand, are plotted as a function of protein
sequence. Error bars are determined from the effect of background noise on peak height (SD). Gaps in the plots occur for residues with unassigned or very weak
peaks in the HSQC or for prolines.
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Figure 4. SAXS Data for FBN1E2cbEGF1 Reveals a Linear Shape
(A) Scaled, merged, and averaged X-ray scattering curves collected with purified FBN1E2cbEGF1 at concentrations of 11.55, 5.78, 2.89, and 1.44 mg/mL. Analysis
of these data confirm that the protein behaves as a monomer in solution.
(B) Kratky plot of scaled, merged, and averaged SAXS data showing a peak falling to a plateau; this behavior is characteristic of a folded and relatively rigid
protein.
(C) P(r) distribution and ab initio modeling of particle shape using DAMMIF. The blue transparent surface represents the shape produced from averaging the 20
independently generated ab initio structures with DAMAVER, and the darker spheres within this envelope represent the core shared particle shape calculated by
the DAMFILT algorithm. Fitting this DAMFILT particle shape to the scattering data gave a c2 value of 0.7240.
(D) Comparison of a selectedmodel (black cartoon) from the NMR structural ensemble with the envelope produced by DAMFILT ab initiomodeling (gray surface).
(E) Fitting of the 20 structures in the NMR ensemble to the SAXS data. The SAXS data and error bars are shown in black and gray, respectively. The fits of the NMR
structures are shown in blue with a dark blue dashed line showing the fit of model 1 of the NMR ensemble.
The error bars in (A), (B), and (E) are derived from the SCATTER software package using the data collected at four proteins concentrations.The two-domain LTBP1 constructs were also flowed over a
smaller immobilized FBN1 fragment, FBN1NE3, which shares
the EGF2-EGF3 domains with FBN1E2cbEGF1 (Figures 1A and1212 Structure 25, 1208–1221, August 1, 20172A). The substantially weaker interaction observed for
LTBP1TB3E3 with FBN1NE3 than with FBN1E2cbEGF1 suggests
that the Hyb1 and cbEGF1 domains of FBN1 contain the major
Figure 5. Heteronuclear NOE and RDC Data for FBN1E2cbEGF1
(A) {1H}-15N heteronuclear NOE ratios are plotted as a function of sequence for FBN1E2cbEGF1. Low heteronuclear NOE ratios (<0.5) at the N terminus of EGF2 and
for two loops in Hyb1 (y, *) indicate significant flexibility on a picosecond to nanocsecond timescale in these regions. The residues linking EGF3 to Hyb1, indicated
by a thick black line, show NOE ratios characteristic of a rigid protein backbone demonstrating that the EGF3-Hyb1 linker is not flexible on a fast timescale. Error
bars for the NOE ratio were estimated from 500 Monte Carlo simulations using baseline noise as a measure of the error in the peak heights.
(B) Distribution of RDC values measured in 4% bicelles for the EGF2-EGF3 and Hyb1-cbEGF1 domain pairs of FBN1E2cbEGF1. The different distribution of RDC
values for the two pairs suggests that there may be some slower timescale flexibility at the EGF3-Hyb1 interface. Similar differences in RDC distribution are
observed for RDCs measured in 2.2% C12E6/n-hexanol (data not shown).LTBP1 binding site. The similar strength of interaction of
LTBP1cbEGF14TB3 with FBN1NE3 and FBN1E2cbEGF1 indicates
that the TB3 domain of LTBP1 must interact with the EGF2-
EGF3 region of FBN1. The lack of an interaction between
LTBP1E3cbEGF15 and FBN1NE3 suggests that the EGF3 domain
of LTBP1 must interact with the Hyb1-cbEGF1 region of FBN1.
Dissociation constants (Kd) of 100 ± 20 and 300 ± 100 mM
for the interaction of FBN1E2cbEGF1 with LTBP1E3cbEGF15, and
LTBP1cbEGF14TB3, respectively, can be estimated from the SPR
data (Figure S2). In contrast, the binding of LTBP1TB3E3 to
FBN1E2cbEGF1 gives a non-linear Scatchard plot (Figure S2);
this is not surprising as the multi-site mode of interaction for
this LTBP1 construct may give rise to complicated binding ki-
netics. Nevertheless, a Kd of 0.5–1 mM can be estimated
from the SPR data at the lowest analyte concentrations (which
are similar to concentrations used in previous studies [Mas-
sam-Wu et al., 2010; Ono et al., 2009]). Thus, the pair of interac-
tion sites between FBN1 and LTBP1 results in a substantial
enhancement in overall binding affinity. A cartoon summarizing
our proposed binding model based on our domain dissection
data is shown in Figure 2C.HSQC Titrations of FBN1 and LTBP1 Reveal Distinct
Binding Sites
The SPR studies described above indicated that two sites are
responsible for the interaction of the C-terminal region of
LTBP1 and the N-terminal region of FBN1. To provide residue-
specific information about each binding site, NMR titrations
were carried out with a number of 15N-labeled protein constructs
with assigned heteronuclear single quantum coherence (HSQC)
spectra (Robertson et al., 2013b, 2014). Titrations of the four-
domain FBN1E2cbEGF1 construct with the two-domain LTBP1
construct, LTBP1cbEGF14TB3, exhibit specific chemical shift
changes which identify residues that are involved in the interac-
tion (Figures 3A and 3B); this fast exchange behavior on the NMR
timescale is consistent with the relatively weak interaction be-
tween the two protein constructs seen by SPR. These titrations
show that residues throughout the TB3 domain of LTBP1 interact
with residues located in EGF3 and the N-terminal region of Hyb1
of FBN1 (Figures 3A and 3B). Titration of the four-domain
FBN1E2cbEGF1 construct with the two-domain LTBP1 construct,
LTBP1E3cbEGF15, shows specific broadening effects rather than
chemical shift changes; this indicates intermediate/slowStructure 25, 1208–1221, August 1, 2017 1213
Figure 6. Solution Structural Ensemble of
FBN1E2cbEGF1 and Interaction Sites Mapped
onto the FBN1 and LTBP1 Structures
(A) Cartoon representation of the 20-structure
ensemble of FBN1E2cbEGF1 with structures aligned
to (i) the EGF2-EGF3 domain pair or (ii) the Hyb1-
cbEGF1 domain pair. The EGF, Hyb, and cbEGF
domains are colored in yellow, purple, and green,
respectively, the calcium ion is shown as a red
sphere, and disulfide bonds are shown as dark
gray lines.
(B) Residues identified by peak shifts or peak
broadening in HSQC spectra from FBN1 and
LTBP1 titrations are highlighted on the solution
structure of the EGF2-EGF3-Hyb1-cbEGF1 region
of FBN1 and on a validated homologymodel of the
cbEGF14-TB3-EGF3-cbEGF15 region of LTBP1
(Robertson et al., 2011, 2014). Residues in FBN1
and LTBP1 that experience combined peak shifts
of more than 0.06 and 0.05 ppm, respectively, in
titrations of FBN1E2cbEGF1 with LTBP1cb14TB3 are
shown in orange. Residues in FBN1 and LTBP1
that experience at least a 7- or 10-fold loss of in-
tensity, respectively, in titrations of FBN1E2cbEGF1
with LTBP1E3cbEGF15 are shown in cyan. In both
proteins, residues that have shifts or intensity
changes below the relevant thresholds are shown
in light gray, whereas residues that were not as-
signed are shown in dark gray. See also Figures S3
and S4.exchange behavior consistent with the stronger interaction be-
tween this pair of protein constructs seen by SPR (Figures 3C
and 3D). These titrations show that residues located in the
EGF3 domain of LTBP1, and some of the unstructured region
that immediately precedes EGF3, interact with residues located
in the Hyb1 and cbEGF1 domains of FBN1 (Figures 3C and 3D).
SAXS and NMR Support an Extended Near-Linear
Conformation for FBN1E2cbEGF1 in Solution
To investigate the overall shape of the FBN1E2cbEGF1 frag-
ment and to assess its flexibility in solution, SAXS measure-
ments were collected. Ab initio structural modeling and
analysis of P(r) distributions support the idea of the EGF2-
EGF3-Hyb1-cbEGF1 fragment adopting a linear conformation
in solution. The Kratky plot is also consistent with a folded
protein and does not show signs of significant flexibility (Fig-
ures 4A–4C).
In our previous studies of the C-terminal domains of LTBP1,
{1H}-15N heteronuclear nuclear Overhauser effect (NOE) data
identified the presence of flexible linkers between the cbEGF14,1214 Structure 25, 1208–1221, August 1, 2017TB3, and EGF3 domains (Robertson
et al., 2014). Heteronuclear NOE data
collected here for FBN1E2cbEGF1 show
fast timescale flexibility at the N terminus
of EGF2 and for loop regions in Hyb1 (Fig-
ure 5A). However, no evidence of fast
timescale dynamics is observed for the
residues linking EGF3 to Hyb1. Further-
more inter-domain 1H-1H NOEs are
observedbetween residuesat theC termi-nusof EGF3and theN terminus ofHyb1, consistentwith thepres-
ence of a specific interface (data not shown).
Residual dipolar couplings (RDCs) were collected for
FBN1E2cbEGF1. RDCs are a useful NMR parameter for assessing
the relative orientations of protein domains in solution (Braddock
et al., 2001; Weisshuhn et al., 2016) and were used previously to
confirm the linear orientation of LTBP1 EGF3-cbEGF15 (Robert-
son et al., 2014). The distribution of RDCs observed for the
EGF2-EGF3 and Hyb1-cbEGF1 pairs are not the same, indi-
cating that some slower timescale movement of the domain
pairs relative to each other may exist in solution (Figure 5B).
Overall, these NMR data suggest that EGF3 and Hyb1 form an
interface, but this may not be quite as rigid in solution as the
EGF2-EGF3 and Hyb1-cbEGF1 interfaces.
Solution Structure of FBN1E2cbEGF1
The solution structure of the N-terminal region of FBN1,
comprising the unique N-terminal domain (FUN) and EGF1-3
(Figure 1A), has been determined previously (Yadin et al.,
2013). This showed a rigid orientation of the FUN-EGF1 pair, a
Table 1. NMR Structure Calculation Statistics
FBN1E2cbEGF1
NOE-derived distance restraints
Total 3,222
Total unambiguous 3,072
Intra-residue 1,261
Inter-residue 1,811
Sequential (ji  jj = 1) 726
Short-range (ji  jj < 5) 351
Long-range (ji  jjR 5) 734
Ambiguous 150
Hydrogen bond restraints 78
Dihedral angle restraints 161
RDCs 169
1DNH 2.2% C12E6/n-hexanol 85
1DNH 4% bicelles 84
Calcium-binding restraints 7
Restraint violations (average of full ensemble)
Distance restraint violations >0.5 A˚ 4.35
Dihedral angle violations >5 2.85
RMSD from experimental restraints
Distance restraints (A˚) 0.057 ± 0.003
Dihedral angle restraints () 1.323 ± 0.402
RDC restraints (Hz) 2.155 ± 0.141
RMSD from idealized geometry
Bonds (A˚) 0.007 ± 0.000
Angles () 0.822 ± 0.021
Impropers () 2.50 ± 0.12
Ramachandran plot (%)
Residues in most favored regions 80 ± 2
Residues in additional allowed regions 15 ± 2
Outlier residues 5 ± 1
Coordinate precision (RMSD; A˚)
Backbone
EGF2-EGF3 residues 119–178 0.80
Hyb1-cbEGF1 residues 204–287 0.71
Heavy atom
EGF2-EGF3 residues 119–178 1.17
Hyb1-cbEGF1 residues 204–287 1.15
NOE, nuclear Overhauser effect; RDCs, Residual dipolar couplings;
RMSD, root-mean-square deviation.flexible linker between EGF1 and EGF2, and a rigid orientation of
the EGF2-EGF3 pair. Structural information for the N-terminal re-
gion of FBN1 beyond EGF3, which contains the main LTBP1
binding site, has not been available. Attempts to crystallize the
four-domain FBN1E2cbEGF1 construct were unsuccessful.
Here, thesolutionstructureofFBN1E2cbEGF1wasdeterminedby
a simulated annealing approach using distance restraints derived
from2Dand3DnuclearOverhauser effect spectroscopy (NOESY)
spectra, torsion angle restraints derived from TALOS+ analysis of
chemical shifts (Shen et al., 2009), hydrogen bond restraints
derived from hydrogen-deuterium exchange experiments, RDCrestraints collected in two alignment media, and a linearity re-
straint consistent with the SAXS data (Figure 6A; Table 1). Each
domain within FBN1E2cbEGF1 adopts its expected characteristic
fold. The EGF2-EGF3 and Hyb1-cbEGF1 pairs each contain a
rigid interface defined by extensive NOEs and RDCs, and super-
position of these domain pairs results in relatively low root-mean-
square deviation values (Table 1). The structure and inter-domain
interactions of the EGF2-EGF3 domain pair are consistent with
the previously published solution structure of FBN1NE3 (Yadin
et al., 2013). However, the C-terminal loop of EGF3 is better
defined in the FBN1E2cbEGF1 structure presented here since resi-
dues in this region are involved in specific packing interactions
with the Hyb1 domain that are absent in FBN1NE3 (Robertson
et al., 2013b). The interface formed between Hyb1 and cbEGF1
is characterized by a number of specific side-chain interactions
(Figure S3). The side chains of F235 (Hyb1) and V266 (cbEGF1)
form a packing interaction that is likely to stabilize the Ca2+-bind-
ing site, as similar packing interactions areobserved inother high-
affinity Hyb-cbEGF and TB-cbEGF pairs (Jensen et al., 2009).
The EGF3-Hyb1 interface is less well defined in the solution
structures (Figure S4). NOEs are observed between residues
170–173 in EGF3 and residues 179–183 in Hyb1. The latter res-
idues are restricted to the very N terminus of Hyb1, which is well
defined with respect to the EGF2-EGF3 domain pair. The ambi-
guity in domain orientation hinges around residues 183 and 184,
with only limited NOEs between these ‘‘linking’’ Hyb1 residues
preceding 184 and residues 203, 204, 205, and 217 in the rest
of the Hyb1 domain.
The ensemble of 20 solution structures has been used to back
calculate the SAXS data. All structures give good agreement with
the data with c2 values ranging from 2.7 to 4.6. The overall shape
of the solution structure fits well with the envelope determined
from the SAXS data, supporting an extended arrangement of
the domains (Figures 4D and 4E).
Structural Modeling and Mutagenesis of the LTBP1-
FBN1 Complex
The NMR titration data (Figure 3) can be mapped onto the struc-
ture of FBN1E2cbEGF1 and our previous model of the cbEGF14-
TB3-EGF3-cbEGF15 domains of LTBP1 (Robertson et al.,
2014). Two distinct binding sites are apparent that suggest two
different faces of the FBN1 N terminus are involved in interacting
with the two separate FBN1-binding domains in the LTBP1C ter-
minus (Figure 6B). Since attempts to crystallize the complex
were unsuccessful, HADDOCK, a data-driven protein-protein
docking approach, was used to generate models of the complex
(van Zundert et al., 2016).
Initial calculations, based only on the NMR titration data, iden-
tified a number of possible binding orientations. One common
feature in the models was the presence of salt bridges that
were frequently seen between basic residues in FBN1 and acidic
residues in LTBP1 (Figures 7A and 7B); different pairs of these
residues were involved in the formation of inter-molecular salt
bridges in different models. K138 and R182 of FBN1 and D1521
and D1573 in LTBP1 are involved in salt bridges in HADDOCK
models of the FBN1/LTBP1TB3 complex, while R232 of FBN1
and E1625, E1642 and D1655 of LTBP1 are involved in salt
bridges in models of the FBN1/LTBP1E3cbEGF15 complex. To
test the importance of these potential salt bridges, a number ofStructure 25, 1208–1221, August 1, 2017 1215
Figure 7. Effects of Salt Bridge Substitu-
tions on FBN1-LTBP1 Interactions
(A) Electrostatic surface representation for LTBP1
(cbEGF14-TB3-EGF3-cbEGF15); negatively
charged surface is shown in red and positively
charged surface in blue. Acidic residues identified
in LTBP1 as potential salt bridge partners by pre-
liminary HADDOCK modeling are shown as dark
red spheres. D1521 and D1573 are involved in salt
bridges in HADDOCK models of the FBN1-
LTBP1TB3 complex, while E1625, E1642, and
D1655 are involved in salt bridges in models of the
FBN1-LTBP1E3cbEGF15 complex. Substitution of
underlined residues showed reductions in binding.
(B) Electrostatic surface representation for FBN1
(EGF2-EGF3-Hyb1-cbEGF1). Basic residues iden-
tified in FBN1 as potential salt bridge partners in
initial HADDOCK modeling are shown as dark blue
spheres. K138 andR182 are involved in salt bridges
in HADDOCK models of the FBN1-LTBP1TB3 com-
plex, while R232 is involved in salt bridges inmodels
of the FBN1-LTBP1E3cbEGF15 complex.
(C) Simplified model representing charge-charge
interactions between theHyb1domain of FBN1and
the TB3 and EGF3 domains of LTBP1 with domains
colored as in Figure 1.
(D) Plot of SPR responses from binding of WT
LTBP1TB3E3 analyte to three different FBN1E2cbEGF1
constructs immobilized to different flow cells of the
same chip.
(E) Plot of SPR responses from three different
LTBP1TB3E3 constructs binding immobilized WT
FBN1E2cbEGF1. See also Figures S1 and S5; Ta-
ble S2.charge-reversal substitutions were introduced in FBN1 and
LTBP1. Variant proteins were produced (Figure S1) and their in-
teractions assessed using SPR and plate-based assays.
Variants of FBN1 containing the R182E and R232E substitu-
tions, and variants of LTBP1 containing the D1573R and
D1655R substitutions, all showed reduced binding to wild-type
(WT) LTBP1 and FBN1, respectively (Figures 7D, 7E, and S5),
while substitutions K138D, D1521K, E1625R, and E1642R did
not (data not shown). D1655R and R232E had the larger effect
on binding consistent with a role for these residues in the stron-
ger LTBP1-EGF3/FBN1-Hyb1 interaction (Figure 7C). No further
reduction in binding was observed for the interaction of FBN1-
R232E and LTBP1-D1655R constructs (Figure S5); if these resi-
dues acted independently, as part of two separate salt bridges,
then an additive effect and a further reduction in binding would
be expected (Hwang and Warshel, 1988; Venkatachalan and
Czajkowski, 2008). A similar observation is made for the FBN1-
R182E/LTBP1-D1573R interaction. These results are consistent
with specific salt bridges forming between R232 and D1655 and
between R182 and D1573 in the interaction of FBN1 with LTBP1
(Figure 7C).
The identification of residues in salt bridge interactions stabi-
lizing the complex allowed refinement of the HADDOCK models1216 Structure 25, 1208–1221, August 1, 2017by including specific distance restraints
in each calculation. Figure 8A shows an
overall model of the complex created bysplicing together the best clusters obtained from docking of
LTBP1 TB3 and EGF3-cbEGF15 with FBN1E2cbEGF1. In the
HADDOCK model of the FBN1/LTBP1 complex, the distance
separating the last residue of LTBP1-TB3 and the first residue
of LTBP1-EGF3 is small enough to be easily accommodated
by the 36-residue flexible linker joining the two domains (Fig-
ure 8A). An LTBP1TB3E3 variant in which this linker was deleted
showed lower binding to FBN1E2cbEGF1 in a plate-based assay
(Figures 8B and 8C), consistent with only one of the two
LTBP1 domains being able to interact at any given time in this
construct. Replacement of the LTBP1 linker with the shorter
22-residue linker from LTBP3, which has a very different amino
acid sequence, restored binding to levels comparable with the
WT interaction indicating the linker plays a passive role as a
connector (Figures 8B and 8C).
Biological Significance of FBN/LTBP Interaction
Our solution structure of a four-domain FBN1 fragment, EGF2-
EGF3-Hyb1-cbEGF1, identifies a near-linear domain organi-
zation, which, together with the previously determined NE3
structure, reveals the complete structural organization of the
N-terminal region of FBN1 (Figure 9A). The extended shape of
FBN1, but with a flexible linker between EGF1 and EGF2, may
Figure 8. Model of LTBP1-FBN1 Interaction
Derived from HADDOCK and Role of LTBP1
TB3-EGF3 Linker in the Interaction
(A) Combined interaction model for FBN1 and
LTBP1 created by merging the best models
calculated for the two interaction sites. The EGF2-
EGF3-Hyb1-cbEGF1 domains of FBN1 are shown
in blue and the TB3-EGF3-cbEGF15 domains of
LTBP1 are shown in green. The side-chain atoms
of residues that form salt bridges are shown as
spheres. The dotted lines represent one of many
possible positions for the flexible linkers that in
LTBP1 join the C terminus of cbEGF14 to the
N terminus of TB3 (green dotted line) and the
C terminus of TB3 to the N terminus of EGF3
(green dotted line highlighted in red). Inset:
cartoon summarizing the layout of protein do-
mains shown.
(B) Plate-binding assay, with the FBN1E2cbEGF1
construct immobilized on the plate surface, shows
the effect of modifying the TB3-EGF3 linker in
LTBP1. Deletion of the linker in LTBP1TB3E3 leads
to a weakening of the interaction in comparison
with WT LTBP1. Replacement of the LTBP1 linker
with the LTBP3 linker shows binding similar to the
WT construct. The data shown here are repre-
sentative; they are taken from a single plate with
three repeats of each protein concentration car-
ried out to determine experimental error (SD).
(C) Sequence alignment of the TB3-EGF3 region of
LTBP1 and LTBP3 shows little or no sequence
homology between the two linker regions. Regions
of the linker deleted or replaced are highlighted by
boxes. See also Figures S1 and S6; Table S1;
Data S1.help expose multiple binding sites that allow FBN1 to act as an
interaction hub, with numerous protein-protein interactions re-
ported for this region including LTBP1 and 4 (Ono et al., 2009),
fibulin-2, -4, and -5 (Choudhury et al., 2009; El-Hallous et al.,
2007; Ono et al., 2009), and ADAMTS10 (Kutz et al., 2011).
Our detailed dissection of LTBP1 binding to FBN1 EGF2-
EGF3-Hyb1-cbEGF1 has identified a bipartite mode of interac-
tion, with the C-terminal region of LTBP1 utilizing two discrete
sites to anchor itself to FBN1. The two orders of magnitude
change in Kd seen when the binding of LTBP1
TB3E3 (0.5–
1 mM), which contains two binding sites, is compared with the
binding of the LTBP1E3cbEGF15 and LTBP1cbEGF14TB3 fragments
(100 and 300 mM, respectively), which contain single binding
sites, is similar to other bipartite interactions mediated by
modular proteins. For example, in a collagen/fibronectin interac-
tion, two individual sites with Kd values of 2 mM and 248 mM,
combine to give a Kd of 26 mM (Erat et al., 2013). For fibronectin
F1 modules which interact with streptococcal SfbI peptides, two
sites with Kd values of 159 and 63 mM combine to give a Kd of
0.45 mM (Schwarz-Linek et al., 2004).
While our measured binding affinities for LTBP fragments, in
simple assays, are relatively weak, these affinities are not atyp-
ical of other modular protein interactions. Our estimated Kd of
0.5–1 mM for the FBN1E2cbEGF1/LTBP1TB3E3 interaction repre-
sents a 4- to 25-fold weaker binding than reported in previous
SPR studies; the variation in reported Kd values may arise
from methodological differences (Massam-Wu et al., 2010;Ono et al., 2009). Sincemodular ECMproteins oftenmultimerize
or have multiple binding sites for proteins/proteoglycans/gly-
cosaminoglycans, additional strategies are likely to further in-
crease binding of LTBP to the matrix. Recently multimerization
of LTBP1 has been observed, which is enhanced by heparin
(Troilo et al., 2016). Higher-order assembly of LTBP1, together
with the bipartite interaction reported here, may allow LTBP1
to achieve a strong interaction with FBN1 in the dynamic envi-
ronment of connective tissues, while maintaining contacts
with other ECM protein networks and/or cell/matrix compo-
nents (Figure 9B).
It has been reported previously that the interaction between
FBN1 and LTBP1 is much stronger than that involving FBN2
and LTBP1 (Isogai et al., 2003). Comparison of the sequences
of human FBN1 and FBN2 shows complete conservation of res-
idues involved in the stronger FBN Hyb1-cbEGF1/LTBP1 EGF3
interface,whereas three substitutions are observed in theweaker
FBNEGF3-Hyb1/LTBP1 TB3 interface (Figure S7). A reduction of
binding affinity in the latter site could explain the observed differ-
ences in binding for FBN1/FBN2. It has also been suggested that
the mode of interaction of FBN1 with the LTBP1 and LTBP4
isoforms differs (Ono et al., 2009). Comparison of the sequences
of human LTBP1 and LTBP4 shows substitutions in both
binding sites (Figure S7). Some of these substitutions alter the
electrostatic properties of the LTBPs. Interestingly, an N164S
substitution in FBN1 EGF3, associated with dominant ectopia
lentis (Comeglio et al., 2002), has been reported previously toStructure 25, 1208–1221, August 1, 2017 1217
Figure 9. Molecular Model for Presentation
of TGF-b by LTBP1 in the ECM
(A) Structure of the FBN1 N terminus constructed
from the structure presented here (5MS9) and the
previously published structure of NE3 (2M74). The
linker between EGF1 and EGF2 is flexible on a fast
timescale as shown by an arrow. Domains are
colored as in Figure 1 and the top right inset shows
the minimal regions required for specific protein
interactions.
(B) Model of LAP and fibrillin binding of LTBP1S
constructed using the program Modeller and co-
ordinate files PDB: 1UZJ, 1EMN, and 1KSQ.
LTBP1 atoms are represented as spheres colored
by domain as in Figure 1, while FBN1 is colored
slate blue and shown as a ribbon with transparent
surface rendering. For the known flexible linkers in
LTBP1 only the Ca atoms are shown (gray
spheres). For scale, the structure of TGF-b (dark
red ribbon and surface) bound to LAP (orange
ribbon) from PDB: 3RJR (Shi et al., 2011) is
included next to the second TB domain of LTBP1,
which binds the small latent complex covalently
via a disulfide linkage. LTBP1 can also bind to
other ECM fibers via its N terminus (Robertson
et al., 2015), and to cell-surface integrins via the
RGD motif in LAP. Integrins are thought to bind
LAP in order to exert traction and release TGF-b.decrease the binding affinity of FBN1 to LTBP4, but not to LTBP1
(Ono et al., 2009). N164 is not directly involved in the LTBP1 bind-
ing site in our model of the complex; instead its side chain is
located on the opposite face of the FBN1 EGF3 domain. The
reduction in binding to LTBP4 suggests that the binding interface
must be different in the FBN1/LTBP4 complex.
To conceptualize the significance of the LTBP1-FBN1 interac-
tion, a large-scale model of LTBP1 was generated, with the small
latent complex of LAP/TGF-b also included for scale (Figure 9B).
It can be seen that the short flexible linker identified previously1218 Structure 25, 1208–1221, August 1, 2017between cbEGF14 and TB3 in LTBP1
(Robertson et al., 2014) may serve as an
omnidirectional pivot that helps LTBP to
maintain its contacts with other networks
and to orient latent TGF-b for activation
by integrins or other factors. It is possible
that FBN microfibrils (together with other
ECM networks) contribute directly to the
efficiency of activation of TGF-b since
the unusual bipartite nature of the LTBP
interaction may allow the LTBP/FBN
complex to resist integrin-mediated trac-
tion or other dynamic changes in connec-
tive tissue, while TGF-b is released from
the LAP complex. Integrin-mediated acti-
vation of TGF-b has been shown to be
heavily reliant on matrix biomechanics
(Buscemi et al., 2011; Klingberg et al.,
2014), and at present integrins are the
only TGF-b activators that have been
clearly demonstrated to be crucial in vivo
(Robertson and Rifkin, 2014; Yang et al.,2007). In Marfan syndrome, loss-of-function FBN1 mutations
result in a deficiency of 10–12 nm microfibrils in the ECM. While
LTBP may still be able to bind to other ECM networks such as
fibronectin, despite the reduction in FBN, ECM biomechanics
may be altered sufficiently in the absence of microfibrils that
TGF-b is inappropriately released from the LAP complex when
integrins bind. This might explain why in vivo deletion of the
Hyb1 domain, which does not impair microfibril assembly and
contains the major binding site for LTBP1, did not result in any
Marfan-like phenotypes (Charbonneau et al., 2010).
Proteases like BMP1 have been proposed to regulate TGF-b
signaling during normal development by cleaving the C terminus
of LTBP1 and releasing it from the ECM (Ge and Greenspan,
2006). The presence of a flexible linker between the two FBN1-
interacting sites within LTBP1 suggests a mechanism by which
proteases can regulate the affinity of this interaction. Protease
cleavage of the TB3–EGF3 linker in LTBP1 may release the large
latent complex from the 10–12 nm microfibril network, as the af-
finity of the TB3 binding site alone for FBN1 is very much weaker
than the bipartite interaction. Cleavage may also significantly
reduce the affinity of the remaining EGF3-cbEGF15 LTBP1 frag-
ment for FBN1, facilitating turnover.
In summary, we have completed the structure of the FBN1
N-terminal region, explaining its role as an interaction hub in
the ECM. We have further demonstrated an unusual bipartite
interaction of LTBP1 with FBN1, adjacent to the LAP/TGF-b
binding site, which facilitates complex formation in dynamic con-
nective tissues. We propose that this contributes to integrin-
mediated activation of TGF-b in FBN1-rich tissues.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-RGS-His antibody conjugated with HRP Qiagen 34450
Bacterial and Virus Strains
BL21 pREP4 Lab strain N/A
XL10 Gold Agilent 200315
Chemicals, Peptides, and Recombinant Proteins
FBN1NE3 (Yadin et al., 2013) N/A
FBN1E2cbEGF1 and variants This work and (Robertson et al., 2013b) N/A
FBN1cbEGF22TB4cbEGF23 (Jovanovic et al., 2007) N/A
LTBP1TB3cbEGF15 This work N/A
LTBP1TB3E3 and variants This work and (Robertson et al., 2014) N/A
LTBP1cbEGF14TB3 This work and (Robertson et al., 2014) N/A
LTBP1E3cbEGF15 This work and (Robertson et al., 2014) N/A
15N ammonium chloride Goss Scientific NLM-467
13C Glucose Goss Scientific CLM-1396-5
D2O Sigma Aldrich 151882-125 G
Chelating Sepharose GE Healthcare 17-0575-01
Deposited Data
BMRB NMR assignments (Robertson et al., 2013a, 2014; Robertson
et al., 2013b)
19078, 18848, 19322
Fibrillin E2cbEGF1 NMR structure This paper 5MS9
Oligonucleotides
18 Site directed mutagenesis primers listed in Table S2 This work N/A
Recombinant DNA
FBN1NE3 – in pQE30 expression vector (Yadin et al., 2013) N/A
FBN1E2cbEGF1 and variants - in pQE30 expression vector This work and (Robertson et al., 2013b) N/A
FBN1cbEGF22TB4cbEGF23 – in pQE30 expression vector (Jovanovic et al., 2007) N/A
LTBP1TB3cbEGF15 – in pQE30 expression vector This work N/A
LTBP1TB3E3 and variants – in pQE30 expression vector This work and (Robertson et al., 2014) N/A
LTBP1cbEGF14TB3 – in pQE30 expression vector This work and (Robertson et al., 2014) N/A
LTBP1E3cbEGF15 – in pQE30 expression vector This work and (Robertson et al., 2014) N/A
Software and Algorithms
ARIA 2.3 (Rieping et al., 2007) N/A
Xplor-NIH 2.29 (Schwieters et al., 2003) N/A
MolProbity (Chen et al., 2010) N/A
HADDOCK server (van Zundert et al., 2016) N/A
TALOS+ (Shen et al., 2009). N/A
ATSAS software package (Petoukhov et al., 2012) N/A
CCPN software (Vranken et al., 2005) N/A
NMRPipe (Delaglio et al., 1995) N/A
Other
ELISA plates R&D systems DY990
Biacore SPR CM5 sensor chips GE healthcare BR100530
e1 Structure 25, 1208–1221.e1–e5, August 1, 2017
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contacts, Penny
Handford and Christina Redfield (penny.handford@bioch.ox.ac.uk and christina.redfield@bioch.ox.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Strains Used in Protein Production
The FBN1 and LTBP1 protein fragments used in this study were expressed in Escherichia coli BL21 cells transformed with a pQE-30
(Qiagen) expression vector and pREP4 plasmid for control of expression via the lac repressor. When cloned into the expression vec-
tor, an N-terminal His6 tag was included for purification, followed by an Ser-Ala spacer and a factor Xa protease recognition site
(Ile-Glu-Gly-Arg) for later removal of the His6 tag.
METHOD DETAILS
Protein Production and Purification
Sequences encoding the EGF2-EGF3-Hyb1-cbEGF1 region of human FBN1 and the cbEGF14-TB3-EGF3-cbEGF15 region of hu-
man LTBP1 were cloned into the pQE30 vector (Qiagen). The additional cysteine in the FBN1 Hyb1 domain (C204) was replaced
with a serine as described previously (Jensen et al., 2009). This change was necessary to allow effective in vitro refolding of the
FBN1 protein fragment. Site-directed mutagenesis was carried out using the QuikChange protocol (Agilent) (for details of primers
used see Table S2).
Protein expression and purification was carried out in a similar fashion to that described previously (Knott et al., 1996) but with
modifications for each construct (Robertson et al., 2013a, 2013b, 2014; Yadin et al., 2012). Unlabelled proteins were expressed in
E. coli grown on unlabelled rich medium. Proteins were single or double labelled with 15N or 15N/13C by growing cells in M9 medium
containing 0.1% (w/v) 15NH4Cl and 0.5% (w/v)
13C-glucose (Goss Scientific), in the presence of 100 mg/ml ampicillin and 25 mg/ml
kanamycin. 50 ml of starter culture, grown in unlabelled M9 medium at 37 C for18 hours, was used to inoculate 600 ml of labelled
M9 medium. Bacteria were grown until OD600 reached 0.8, at which point expression was induced with isopropyl-b-D-thiogalac-
topyranoside (IPTG) at a final concentration of 1 mM. Cells were then incubated at 28 C for 20 hours, harvested by centrifugation
and frozen at 80 C prior to protein purification.
Proteins were purified from inclusion bodies (Robertson et al., 2013a, 2013b, 2014; Yadin et al., 2012). The solubilised His-tagged
proteins were purified using Ni2+ affinity chromatography using fast-flow chelating Sepharose (Amersham Pharmacia or GE Health-
care). His-tagged proteins were eluted with buffer containing 50 mM EDTA. The eluted proteins were then reduced with 200 mM
DTT, buffered with 0.1 M Tris-HCl pH 8.3 and left for at least 1 hr at room temperature to allow for full reduction of the protein. The
reduced protein solutions were acidified to pH 2-3 with HCl and dialysed overnight at room temperature against 2 L of 0.1% trifluoro-
acetic acid (TFA). Protein was then desalted by high performance liquid chromatography (HPLC) using a C8 reverse phase column
(Rainin).
Purified, reduced proteins were refolded in an aqueous solution of 0.2 mg/ml reduced protein, 100 mM Tris-HCl pH 8.3, 3 mM
cysteine and 0.3 mM cystine, and up to 50 mM CaCl2; 50% (v/v) glycerol was included for refolding of FBN1
E2cbEGF1 and FBN1NE3
(to enhance protein solubility) but was not necessary for refolding of LTBP1 constructs. The solution was then left for 48-72 hrs at 4C.
After this period the refold mixture was acidified to pH 2-3 with HCl, and dialysed against 0.1% (v/v) TFA overnight. Dialysate was
centrifuged and filtered to remove any precipitate, concentrated by ultrafiltration, filtered again, and then purified by HPLC.
The His6 tag was cleaved off for all constructs, except LTBP1
TB3E3 and LTBP1TB3cbEGF15, by incubation with factor Xa (Novagen),
carried out with a protein concentration of 1.5-5mg/ml and 1 unit factor Xa permg protein, and incubated at 37 Covernight. Proteins
were further purified by fast protein liquid chromatography (FPLC) using a MonoS 5/50 GL or a MonoQ 5/50 column (GE Healthcare)
depending on protein solubility. After FPLC all proteins were acidified to pH 2, filtered to remove any precipitate, and desalted by
further HPLC purification, before final lyophilisation. The final products were analysed by SDS-PAGE (Figure S1), electrospray ion-
isation mass spectrometry, and 2D 1H-1H NOESY spectra, and were shown to be monomeric and correctly folded.
Protein Interaction Experiments
Plate-based interaction experiments were carried out by incubating DY990 plates (R&D systems) with 50 ml FBN1E2cbEGF1 in 50 mM
carbonate buffer at pH 9.6 for a minimum of 48 hours. Plates were then blocked with 5% BSA carbonate buffer for one hour. Wells
were washed with 100 ml interaction buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.05% (v/v) Tween-20, 2 mM CaCl2) and 50 ml LTBP1
protein samples were then added. At this stage wells were aspirated and aliquoted individually to avoid plate drying. Plates were
incubated with LTBP1 samples for 12 hours and then washed. A 1:5000 dilution of an anti-RGS-His antibody conjugated with
HRP (Qiagen 34450) was then added to each well and incubated for 1 hour to detect LTBP1 binding. Data presented in figures
are representative examples of several experiments carried out at different times (for additional information see QUANTIFICATION
AND STATISTICAL ANALYSIS section below).
SPR studies were carried out using a Biacore T100 instrument (GE Healthcare) with FBN1 fragments coupled to the surface of a
CM5 sensor chip by amine coupling and then washed with 50 mM HCl. The Biacore coupling wizard was used to ensure that anStructure 25, 1208–1221.e1–e5, August 1, 2017 e2
equivalent 1000 RU of protein was coupled to each flow cell. The sensor chip was equilibrated with SPR running buffer consisting of
50mM Tris pH 7.5, 150mM NaCl, 0.05% (v/v) Tween 20 and 2mM CaCl2. Freeze-dried LTBP1 proteins were dissolved directly into
SPR buffer to generate analyte stock solutions. The protein concentrations in these stock solutions were measured by UV-visible
spectroscopy. All SPR experiments were performed at 25C, with a flow rate of 20 ml per minute, and a 30 second 50mMHCl injection
was used for regeneration after each run. Both Multi-cycle and single-cycle programs were used depending on program availability
and the volume of data needed. All four flow cells of the chip were used, one as a blank for baseline subtraction, one with the
FBN1E2cbEGF1 fragment bound, one with FBN1NE3 bound, and finally one with a negative control FBN1 fragment spanning the
cbEGF22-TB4-cbEGF23 domains bound. In this way all flow cells were simultaneously exposed to the same LTBP1 protein analyte
solutions. Kd values were estimated, where possible for lower affinity interactions, from linear Scatchard plots. In some cases,
despite the clear specificity of binding (shown by lack of binding to a control FBN1 fragment or the blank and control treated flow
cells), the Scatchard plots were non-linear; this is not surprising because the multi-site mode of interaction for the higher affinity
LTBP1 constructs may give rise to complicated binding kinetics.
NMR Spectroscopy
NMR experiments were carried out using spectrometers operating at 1H frequencies ranging from 500 to 950 MHz. The spectrom-
eters were equipped with Oxford Instruments magnets and home-built triple-resonance pulsed-field gradient probes (500, 600, 750
and 950 MHz) or with Bruker Avance consoles and TCI CryoProbes (500 and 750 MHz). NMR data were acquired using either
GE/Omega software using pulse sequences written in-house, or Topspin software and pulse sequences in the Topspin libraries
from Bruker Biospin. NMR data were processed using NMRPipe (Delaglio et al., 1995) and spectra were analysed using the
CCPN software (Vranken et al., 2005).
Resonance Assignments
Resonance assignments for FBN1E2cbEGF1, LTBP1E3cbEGF15 and LTBP1cbEGF14TB3 have been described previously (Robertson et al.,
2013a, 2013b, 2014) (BMRB accession numbers 19078, 18848, 19322, respectively). Unless otherwise stated, all NMR experiments
were carried out at 25C at pH 5.4 in 95% H2O/5% D2O with 5mM CaCl2.
Protein Interactions Monitored by NMR
Interactions between LTBP1 and FBN1 fragments were monitored using 2D 1H-15H HSQC spectra collected at 500 MHz. Initially an
HSQC spectrum was collected for the 15N-labelled protein sample alone, and then successive freeze dried aliquots of the unlabelled
interaction partner were added, with the pH of the NMR sample measured before and after each addition, and adjusted prior to
running each HSQC experiment. Initial experiments utilising the LTBP1TB3E3 and FBN1E2cbEGF1 fragments were not informative
because uniform broadening of all signal in the HSQCwas observed,most likely due to slow exchange effects caused by strong bind-
ing of the large LTBP1 fragment.
The interaction of LTBP1E3cbEGF15 with FBN1E2cbEGF1 was monitored in two titrations using either 15N-labelled LTBP1E3cbEGF15 or
15N-labelled FBN1E2cbEGF1. In both titrations 300 ml of a 300 mM 15N sample was used at pH 5.5, with 100mMNaCl and 10mMCaCl2.
The concentration of the unlabelled LTBP1E3cbEGF15 or FBN1E2cbEGF1 ligand ranged from 0 to 250 mM. In these titrations, peaks were
observed to shift; the combined chemical shift change, reported in Figure 3, was determined as DCOMB=((D1HN)
2+(D15N/6)
2)1/2 where
D1HN and D15N are the observed chemical shift differences for
1HN and 15N in HSQC spectra collected with 0 and 250 mM ligand
protein.
The interaction of LTBP1cbEGF14TB3 with FBN1E2cbEGF1 wasmonitored in two titrations using either 15N-labelled LTBP1cbEGF14TB3 or
15N-labelled FBN1E2cbEGF1. In the first titration 300 ml of a 300 mM15N-LTBP1cbEGF14TB3 sample was used at pH 5.9 with 20mMCaCl2.
In the second titration 290 ml of a 300 mM 15N FBN1E2cbEGF1 sample was used at pH 5.3 with 15 mM CaCl2 (slight differences in con-
ditions were necessary to optimise protein solubility). The concentration of the unlabelled LTBP1cbEGF14TB3 or FBN1E2cbEGF1 ligand
ranged from 0 to 250 mM. In these titrations specific losses in peak intensity were seen with successive protein additions. To quantify
peak intensity changes during the titration, peak intensities in the first HSQC experiment without added ligand protein were divided
by the peak intensities in the final titration point. Errors bars represent the error introduced by background noise in the spectrum.
Heteronuclear NOE
{1H}-15N heteronuclear NOE experiment was carried out using 15N-labelled FBN1E2cbEGF1 in order to examine the sub-nanosecond
dynamics of specific amides (Kay et al., 1989). Spectra with and without 1H saturation were collected as interleaved experiments
collected at 750 MHz. 1H saturation was applied for 4 s. The data set was acquired with 1K complex points in F2 and 128 complex
t1 increments; 96 scans were collected per increment. The {
1H}-15N NOE was calculated as the ratio of the peak intensities in the
spectra recorded with andwithout 1H saturation. Peak heights were determined using in-house peak-picking software. Uncertainties
in the NOE ratios were estimated from 500Monte Carlo simulations using baseline noise as ameasure of the error in the peak heights.
Residual Dipolar Couplings
Residual dipolar couplings (RDCs) were collected for the FBN1E2cbEGF1 construct in two liquid crystallinemedia. One set of RDCswas
collected with a 2.2%C12E6/n-hexanol (Sigma-Aldrich) solution in 90%H2O/10%D2O at pH 5.3with 5mMcalcium chloride (R€uckert
andOtting, 2000). The second set of RDCswas collectedwith 4% (w/v) bicelles comprising the ether linked lipids 1,2-O-ditridecyl-sn-
glycero-3-phosphocholine and 1,2-dihexyl-sn-glycero-3-phospho-choline (Avanti Polar Lipids), as well as cetyl trimethyl ammonium
bromide (Sigma-Aldrich) in amolar ratio of 35:10:1 in 90%H2O/10%D2O at pH 5.5with 5mMcalcium chloride (Ottiger andBax, 1998;
Ramirez and Bax, 1998). Interleaved IPAP experiments (Ottiger et al., 1998) were performed at a 1H frequency of 600MHz at 25C (or
35C for the bicelles) using 128 and 1024 complex points in F1 (
15N) and F2 (
1H), respectively. Isotropic spectra were also collectede3 Structure 25, 1208–1221.e1–e5, August 1, 2017
under comparable conditions and residual dipolar couplings were measured as the difference between the splitting observed in the
isotropic and aligned data sets.
SAXS
Small Angle X-ray Scattering data were collected at beamline BM29 at the ESRF in Grenoble, France. Lyophilised protein was dis-
solved in buffer containing 20 mM MES at pH 5.4, 5 mM CaCl2, and 5% glycerol. This solution was then further dialysed against a
large volume of the same buffer and a sample of this buffer used as a blank in the beam line to ensure correct matching. Scattering
data were collected at four different protein concentrations and the data from these samples were scaled and averaged for further
analysis. Guinier analysis was performed using the SCATTER software package and ab initiomodelling and structure fitting was per-
formed using the DAMMIF and CRYSOL programs in the ATSAS software package (Petoukhov et al., 2012) Ab initiomodelling was
performed using ‘slow’ mode with 20 repetitions and default settings for modelling globular proteins. When NMR structures were
fitted to the SAXS data using CRYSOL the 7 flexible N-terminal residues of FBNE2cbEGF1 were removed as this random unstructured
element could significantly affect the fitting.
Structure Determination
NMRexperiments for structure determination were carried out using 15N or 13C/15N labelled FBN1E2cbEGF1 at a concentration of 1mM
at pH 5.4 and 25C. Distance restraints for structure calculation were derived from several 2D and 3D NOESY spectra. The 3D
15N-edited NOESY-HSQC spectrum (mixing time 150 ms) was acquired at 950 MHz in 95% H2O/5% D2O. 3D
13C-edited
NOESY-HSQC spectra (mixing time 75 ms) were acquired at 500 and 950 MHz in 95% H2O/5% D2O (v/v) and 100% D2O, respec-
tively. An aromatic 3D 13C-edited NOESY-HSQC spectrum (mixing time 150ms) was acquired at 750MHz in 95%H2O/5%D2O (v/v).
A 2D 1H-1H NOESY spectrum (mixing time 150 ms) was acquired at 950 MHz in 100% D2O. NOESY cross peaks were assigned
manually in CCPN Analysis using published resonance assignments (Robertson et al., 2013b). In some cases only ambiguous
peak assignments were possible initially.
f and c torsion angle restraints were obtained using TALOS+ predictions on the basis of assigned chemical shifts (Shen et al.,
2009). Hydrogen bond restraints were based on slowly exchanging amides identified in HSQC spectra collected in D2O and observed
NOEs characteristic of regular secondary structure.
Comparison of the distribution of RDC values for the EGF2-EGF3 pair and the Hyb1-cbEGF1 pair showed that they are not the
same indicating that some slower timescale movement of the domain pairs relative to each other may exist in solution (Figure 5B);
this was the case for both alignment media used. In order not to bias the definition of the EGF3-Hyb1 interface in structure calcula-
tions, the RDC data for the EGF2-EGF3 and Hyb1-cbEGF1 pairs were treated separately in the structure calculations (i.e. different
reference alignment tensors used). Values for the axial and rhombic components for the alignment tensors were calculated from the
previously determined structure of NE3 and from a homology model for Hyb1-cbEGF1 using in-house software. For the EGF2-EGF3
pair Da/R values of -13.9/0.56were used for the bicelle data and values of -19.0/0.54were used for theC12E6/n-hexanol data. For the
Hyb1-cbEGF1 pair Da/R values of 11.2/0.35 were used for the bicelle data and values of 15.7/0.50 were used for the C12E6/n-hex-
anol data.
Structures were calculated initially using ARIA 2.3 (Rieping et al., 2007); this was useful for obtaining assignments for ambiguous
NOEs and for validating the allocation of NOE restraints into distance bins. However, the four-domain topology and the 13 disulphide
bonds in FBN1E2cbEGF1 resulted in a limited number of converged structures using this protocol. Subsequent structure calculations
were performed using Xplor-NIH 2.29 (Schwieters et al., 2003). Initially, 800 structures were calculated from an extended starting
structure using a simulated annealing protocol (initial T=2000K, 30000 high temperature steps, 40000 and 20000 steps in cooling to
1000K and 100K, respectively) using NOE, hydrogen bond, disulphide bond and torsion angle restraints. The Ca2+-binding site was
defined using distance restraints between the Ca2+ ion and the cbEGF consensus ligands (Downing et al., 1996). A ’Rama’ torsion
angle database potential was used (Kuszewski et al., 1996). The 20 lowest energy simulated annealing structures were used as the
starting point for refinement (initial T=1500K, 20000 cooling steps) generating a total of 400 structures; the 5 lowest energy structures
from each of the 20 starting structures were selected for further refinement using the two sets of RDC restraints. Refinement was
carried out using 100 starting structures (initial T=1500K, 20000 cooling steps). A square well potential and a force constant of 0.5
were used for the SANI terms with experimental error for the RDCs in the range of 2-4 Hz. 40 structures were selected from the family
of 2000 RDC-refined structures for a final round of water refinement. Thewater-refined structures were used to predict the SAXS data
and a final family of 20 structures was chosen on the basis of low restraint and overall energies and a good fit to the SAXS data. Ram-
achandran validation statistics were calculated using MolProbity (Chen et al., 2010).
Modelling the FBN1/LTBP1 Complex Using HADDOCK
Docking was carried out using the ‘guru’ interface of the HADDOCK server (van Zundert et al., 2016). Since the TB3 and EGF3 do-
mains of LTBP1 are connected by a flexible linker and their binding sites were mapped separately using the LTBP1cbEGF14TB3 and
LTBP1E3cbEGF15 constructs, HADDOCK modelling of these two interactions was performed separately. Flexibility was introduced
into all protein models, both to account for observed flexible loops and also structural ambiguity. A large number of preliminary cal-
culations was performed using different sets of ambiguous interaction restraints defined using different cut offs applied to the NMR
titration data. From these calculations numerous models were generated that were clustered and sorted on the basis of various
shared features. The results suggested several possible binding orientations, but one common feature in the models was theStructure 25, 1208–1221.e1–e5, August 1, 2017 e4
presence of salt bridges that were frequently seen between basic residues in FBN1 and acidic residues in LTBP1. In the different
binding orientations identified, each employed different charged residues in the formation of inter-molecular salt bridges, allowing
the design of targeted substitutions to test these HADDOCK models. Substitutions introduced were K138D, R182E, and R232E in
FBN1E2cbEGF1, and D1521K, D1573R, E1625R, E1642R, and D1655R in LTBP1TB3E3. Binding of the substituted FBN1 and LTBP1
constructs was assessed using the SPR and plate-based assay as described above for the wild-type constructs.
A final round of HADDOCK calculations was carried out using the restraints derived from the NMR data and the salt bridges iden-
tified by the mutagenesis experiments. The final docking clusters shown in Figure 8, and included as a supplemental pdb file (Data
S1), were based on the docking parameters shown in Table S1. Active and passive residues used to define the ambiguous interaction
restraints were derived from the peak shift and intensity change data shown in Figure 3. Random exclusion of AIR restraints was al-
lowed with 10 partitions (10% of restraints). All molecules were modelled as ‘semi-flexible’ and specific segments listed in the table
were modelled as fully flexible to reflect heteronuclear NOE data and structural ambiguity. Histidine protonation was determined
automatically using MolProbity (Chen et al., 2010).
QUANTIFICATION AND STATISTICAL ANALYSIS
Plate-based assay data to probe protein-protein interactions presented in figures are from a single plate; three repeats of each
protein concentration were carried out to determine experimental error. The data presented are representative examples of several
experiments carried out at different times. The curves fitted to the data were generated using GraphPad with the ‘One site – Total
binding’ option. This takes into account specific binding for which a Kd is fitted, nonspecific binding which is assumed to have a linear
dependence on ligand concentration, and background signal. The Kd values extracted are apparent Kds because the fitting proced-
ure uses total ligand concentration rather than free ligand concentration.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The coordinates of the family of NMR structures of FBN1E2cbEGF1 have been deposited in the Protein Data Bank under accession
number 5MS9 (see Table 1). Resonance assignments for FBN1E2cbEGF1, LTBP1E3cbEGF15 and LTBP1cbEGF14TB3 have deposited in
the BioMagResBank (BMRB) under accession numbers 19078, 18848 and 19322, respectively. A PDB model of the LTBP1-FBN1
interaction, produced by splicing together the two highest scoring HADDOCK result files, is included in the Supplemental Information.e5 Structure 25, 1208–1221.e1–e5, August 1, 2017
